查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496024

全球血液凝固检验市场 - 2024 年至 2029 年预测

Global Coagulation Testing Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 123 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计2022年血液凝固检验市场规模将达29.7215亿美元，预测期内复合年增长率为3.84%，2029年市场总规模将达38688.71亿美元。

进行血液凝固检验以测试止血系统。此测试通常使用凝血计来测量和评估血栓形成的速度和血栓的速度。血管中形成的血块可导致心臟病发作、血栓症或栓塞。透过执行这些测试，您可以避免这些不利的结果。

血液和心血管疾病盛行率不断上升、老年人口不断增加、照护现场(POC)血液凝固检验需求激增，以及配备先进感测器的更快、更易于使用的设备等技术进步正在推动市场发展向前发展做出贡献。

在过去的十年中，新的凝血分析仪测试的引入和技术的快速进步提高了止血实验室的品质和效率。肝臟在止血中发挥重要作用，可防止出血和过度凝血。 CN-6000 和 CN-3000 是 Sysmex 最近在 EMEA 地区推出的全自动新一代凝血分析仪。近期发表的CN-6000和CN-3000配备了四项新功能，满足大批量止血检测的多样化需求。

市场驱动因素：

  • 人口成长预计将扩大全球血液凝固检验市场。

联合国《世界人口展望》资料显示，2022年11月世界人口将达80亿，这是人类发展的重要里程碑。

中国和印度仍是人口最多的两个国家，各占世界人口的近18%，人口均超过10亿人。到2023年4月，印度人口预计将增加至1,425,775,850人，超过中国当地人口。

  • 肝病盛行率的增加预计将加速市场成长。

由于肝臟在凝血过程中起着核心作用，因此急性和慢性肝臟疾病与凝血因子和阻碍要素的结合减少、活化剂清除失败以及血小板数量和品质缺陷有关，由于多种变量，它通常会导致凝血障碍。根据美国肝臟基金会2023年9月的讯息，美国超过1亿成年人患有肝病，已有450万人被诊断出患有肝病。未经治疗的肝病可导致肝功能衰竭和癌症，8,000 万至 1 亿成年人可能患有脂肪肝。

  • 此外，根据美国疾病管制与预防中心 2022 年 11 月的讯息，在美国，肝癌每年影响 25,000 名男性和 11,000 名女性，并导致 19,000 人死亡。

此外，根据英国肝臟信託基金的数据，英国每年有超过 10,000 人死于肝病，这一数字在过去 50 年中增加了四倍。 2022年，英格兰约有9,770人死亡，北爱尔兰有369人死亡，苏格兰有1,237人死亡，里奇有701人死亡，而英国总死亡人数为12,077人。肝病不仅与不平等有关，也与贫穷有关，在苏格兰和英格兰，贫穷地区过早死亡的可能性是富裕地区的四倍。考虑到全球肝病的盛行率，血液凝固检验产业预计在预测期内进一步扩大。

  • 随着医疗保健领域的改善，全球对血液凝固检验的需求预计将增加。

凝血分析仪销售量的增加导致尖端治疗设施、实验室、治疗中心和研究机构的数量激增。预计这些变数将在整个预测期内推动市场扩张。血液凝固检查领域的创新技术进步使检测方法变得更简单、更详细、更准确。

肥胖率的上升需要对血糖值进行广泛的检测，对凝血分析仪的需求也显着增加。由于严重的血液相关疾病的治疗费用昂贵，心血管和血液疾病患者数量的增加是市场成长的驱动力。老年人口的增加也促进了市场规模的扩大。

市场限制因素：

  • 自动凝血系统的高成本可能会阻碍市场成长。

安装全自动凝血系统非常昂贵。血液学家以外的工作人员必须经过训练且有能力。在实验室之外建立严格的品质保证标准更加困难。有关血液凝固检验设备的严格法规、全自动止血设备的高成本以及对血液测试潜在副作用的担忧正在阻碍全球市场的成长。此外，先进止血设备的缓慢采用以及对血液凝固检验设备的创新和先进应用的认识不足也阻碍了市场的成长，特别是在新兴国家。

主要进展

  • 2023 年 5 月 - 西门子 Healthineers 推出 Atellica HEMA 570 和 580 分析仪，这是整合自动化和智慧的下一代血液分析仪。这些分析仪旨在消除工作流程障碍并在大批量血液学检测中实现高通量。 Atellica HEMA 570 分析仪和 Atellica HEMA 580 分析仪旨在提供直觉的介面和多分析仪自动化连接，帮助医生可靠地提供关键的血液学资讯。传统上，血液学测试非常复杂、时间敏感，并且需要经验丰富的工作人员来评估结果。 Atellica HEMA 570 和 580 分析仪旨在消除这些障碍，并实现更快的测试结果和简化的工作流程。
  • 2023 年 3 月 - Sysmex Corporation 与西门子医疗诊断公司签订全球OEM协议，OEM供应止血设备和试剂。该协议允许两家公司以各自的品牌销售止血设备和试剂组合，使他们能够提供更广泛的产品和服务。此次合作旨在透过为世界各地的实验室提供有效的解决方案来满足客户需求的多样化。 Sysmex 和西门子 Healthineers 将提供用于凝血障碍测试、术前出血风险管理以及监测接受抗凝血剂治疗的患者的止血设备。
  • 2022年7月－Horiba在ISTH2022上参展了Yumizen G系列止血试剂和分析仪。公司推出新一代自动化分析仪Yumizen G800和G1550，以及用于血液凝固检查的现成试剂。 Yumizen G 的止血产品线支援高品质、经济高效的出血性疾病筛检和评估。新一代分析仪旨在满足中型和重型临床实验室的凝血、血友病诊断和监测要求。 Yumizen G 系统每次测试只使用一个比色皿，避免浪费和过度消耗。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球血液凝固检验市场：依测试类型

  • 介绍
  • 凝血酶原时间测试
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 纤维蛋白原测试
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 活化凝血时间测试
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 血小板功能检查
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章全球血液凝固检验市场：依最终使用者分类

  • 介绍
  • 医院和诊所
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 诊断中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 门诊治疗中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章全球血液凝固检验市场：按地区

  • 介绍
  • 北美洲
    • 按测试类型
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按测试类型
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按测试类型
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 按测试类型
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按测试类型
    • 按最终用户
    • 按国家/地区

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章 公司简介

  • Abbott
  • Diagnostica Stago, SAS
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific
  • Enzyme Research Laboratories Ltd
  • Sekisui Medical Co., Ltd.
  • Stago Group
  • Coagulation Sciences LLC
  • RUSNANO Group
  • Universal Biosensors
简介目录
Product Code: KSI061611699

The Coagulation Testing market was valued at US$2,972.150 million in 2022 and is expected to increase at a CAGR of 3.84% over the forecast period to reach a total market size of US$3,868.871 million by 2029.

Coagulation tests are conducted to test the hemostasis system. Generally, this test is performed with a coagulometer, which measures and evaluates the rate at which clots form or blood coagulates. A blood clot in a blood vessel can lead to a heart attack, thrombosis, or embolism. By performing these tests, one can avoid these unfavorable outcomes.

A growing prevalence of blood disorders and cardiovascular conditions, an increase in the geriatric population, surging demand for point-of-care (POC) coagulation testing, and technological advancements such as faster and easier-to-use devices with advanced sensors have been contributing to the market growth.

The introduction of new coagulation analyzer tests and rapid advancements in technology have led to an increase in the quality and efficiency of hemostasis laboratories over the past decade. To prevent bleeding and excessive coagulation, the liver plays an essential role in hemostasis. The CN-6000 and CN-3000 are fully automated, next-generation blood coagulation analyzers recently launched by Sysmex in the EMEA region. As part of the CN-6000 and CN-3000, which were recently introduced, four new capabilities have been built to cater to the increasingly diverse needs of high-volume hemostasis testing.

Market Drivers:

  • Rising population is predicted to propel the global market of coagulation testing expansion.

There is an increase in the population of the world which will correlate with increasing healthcare requirement as there will be more incidences of diseases and medical condition including coagulation disorders, according to the United Nations (UN) data on World Population Prospects, the world's population reached 8 billion in November 2022, marking a significant milestone in human development, it expected to reach 9 billion by 2037 while the population is expected to increase by nearly 2 billion in the next 30 years, reaching 9.7 billion in 2050.

China and India remain the two most populous countries, with each representing nearly 18 percent of the world's population both with more than 1 billion individual. In April 2023, India's population was expected to extent to 1,425,775,850 people, surpassing that of mainland China.

  • Increased prevalence of liver disease is expected to surge the market growth.

As the liver is a central player within the clotting process, thus, acute and chronic liver illness regularly leads to coagulation disorders due to a few variables,like decreased amalgamation of clotting and inhibitor factors, an failure to eliminate activated variables, and defects in both amount and quality of platelets. As per American Liver Foundation information from September 2023, more over hundred million U.S. adult individuals suffer from liver disease, with 4.5 million analyzed for it. People with untreated liver disease can lead to liver failure and cancer, with 80-100 million adult people possibly suffering from fatty liver disease and ignorant about it themselves.

  • In addition, as per Centers for Disease and Control and Prevention information of November 2022 Liver cancer influences 25,000 men and 11,000 women within the United States every year, with 19,000 dying from the same.

Moreover, according to British Liver Trust, over 10,000 deaths due to liver disease happen every year within the UK, with a four-fold increment over the past fifty years. In 2022, England had about 9,770 deaths, Northern Ireland had 369, Scotland had 1,237, and Ridges had 701 deaths in total while the UK-wide death number was 12,077. Liver disease is connected to deprivation as well as inequality, with untimely passings being four times higher in deprived regions compared to affluent areas in both Scotland and England. In light of the dominant rate of liver disease globally, the coagulation testing industry will expand at an increasing rate amid the estimate period.

  • Improvements in the Healthcare Sector are anticipated to boost the demand of coagulation testing globally.

The increasing commerce of blood coagulation analyzers have driven to a surge within the advancement of cutting-edge therapeutic facilities, labs, treatment centers, and research organizations. All through the forecasted period, these variables are anticipated to impel market extension. Innovative technological headways in blood coagulation testing have made the method simpler, more detailed, and precise.

Rising obesity rates necessitate extensive testing for blood sugar levels, leading to a massive growth in the demand for blood coagulation analyzers. The increasing population of cardiovascular illnesses and blood disorders is driving market growth, as severe blood-related illnesses can be costly to treat. The geriatric population's growth is also contributing to the market size.

Market Restraints:

  • The high cost of an automated coagulation system could hinder the market growth.

Having a fully automated coagulation system comes at a high cost. Staff members other than hematologists must obtain training and be competent. It is more difficult to establish rigorous quality assurance standards outside the laboratory. Stringent regulations governing coagulation testing devices, the high cost of fully automatic hemostasis equipment, and the concern over the potential side effects of blood testing are inhibiting the growth of the global market. In addition, the slow adoption of advanced hemostasis instruments and the lack of awareness regarding innovative and advanced applications of coagulation test devices are also hampering the market growth, particularly in developing countries

Key Developments:

  • May 2023- Siemens Healthineers introduced the Atellica HEMA 570 and 580 Analyzers, which offer next-gen hematology analyzers with integrated automation and intelligence. These analyzers aim to eliminate workflow barriers and achieve fast throughput in high-volume hematology testing. The Atellica HEMA 570 Analyzer and Atellica HEMA 580 Analyzer are designed to provide intuitive interfaces and multi-analyzer automation connectivity, enabling physicians to deliver critical hematology information reliably. Conventionally, hematology testing is complex and time-sensitive, requiring experienced staff to evaluate results. The Atellica HEMA 570 and 580 Analyzers aim to break down these barriers, enabling faster patient results and improved workflow efficiency.
  • March 2023- Sysmex Corporation and Siemens Healthcare Diagnostics signed a global OEM agreement to supply hemostasis instruments and reagents as OEMs. The agreement allowed both companies to distribute their combined portfolio of hemostasis instruments and reagents under their respective brands, along with their wider products and services. The collaboration aims to diversify customer needs by offering effective solutions to laboratories worldwide. Sysmex and Siemens Healthineers gave hemostasis items utilized in blood clotting disorders testing, preoperative bleeding risk management, and observing patients getting anticoagulant treatment medicines.
  • July 2022- HORIBA Medical displayed its Yumizen G range of hemostasis reagents and analyzers at ISTH 2022 Congress. The company introduced its new generation Yumizen G800 and G1550 automated analyzers, as well as ready-to-use reagents for blood coagulation tests. The Yumizen G hemostasis product range supports high-quality and cost-effective screening and assessment of bleeding disorders. The new-generation analyzers are designed for managing coagulation, thrombophilia diagnostics, and monitoring requirements in clinical laboratories with mid to high workloads. The Yumizen G systems use only one cuvette per test to avoid waste and overconsumption.

Segmentation:

Global Coagulation Testing Market is segmented and analyzed as below:

By Test Type

  • Prothrombin Time Testing
  • Fibrinogen Testing
  • Activated Clotting Time Testing
  • Platelet Function Tests
  • Other

By End Users

  • Hospitals and Clinics
  • Diagnostic Centres
  • Ambulatory Care Centres

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Others
  • Middle East and Africa (MEA)
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL COAGULATION TESTING MARKET BY TEST TYPE

  • 5.1. Introduction
  • 5.2. Prothrombin Time Testing
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Fibrinogen Testing
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Activated Clotting Time Testing
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Platelet Function Tests
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Other
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness

6. GLOBAL COAGULATION TESTING MARKET BY END USERS

  • 6.1. Introduction
  • 6.2. Hospitals and Clinics
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Diagnostic Centres
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Ambulatory Care Centres
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL COAGULATION TESTING MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Test Type
    • 7.2.2. By End Users
    • 7.2.3. By Country
      • 7.2.3.1. United States
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Test Type
    • 7.3.2. By End Users
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Test Type
    • 7.4.2. By End Users
    • 7.4.3. By Country
      • 7.4.3.1. UK
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. Germany
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. France
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Others
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Test Type
    • 7.5.2. By End Users
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Israel
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
      • 7.5.3.4. Others
        • 7.5.3.4.1. Market Opportunities and Trends
        • 7.5.3.4.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Test Type
    • 7.6.2. By End Users
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. India
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. South Korea
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. Taiwan
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Thailand
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Indonesia
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Japan
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Abbott
  • 9.2. Diagnostica Stago, S.A.S.
  • 9.3. F. Hoffmann-La Roche Ltd
  • 9.4. Thermo Fisher Scientific
  • 9.5. Enzyme Research Laboratories Ltd
  • 9.6. Sekisui Medical Co., Ltd.
  • 9.7. Stago Group
  • 9.8. Coagulation Sciences LLC
  • 9.9. RUSNANO Group
  • 9.10. Universal Biosensors